Services - 385103-2022

Unrevised Machine Translation

15/07/2022    S135

Belgium-Brussels: Research and experimental development services

2022/S 135-385103

Contract notice

Services

Legal Basis:
Directive 2014/24/EU

Section I: Contracting authority

I.1)Name and addresses
Official name: Sciensano
National registration number: 0693.876.830_118
Postal address: Rue Juliette Wytsman 14
Town: Bruxelles
NUTS code: BE100 Arr. de Bruxelles-Capitale / Arr. Brussel-Hoofdstad
Postal code: 1050
Country: Belgium
Contact person: Purchasing
E-mail: purchasing@sciensano.be
Telephone: +32 26425371
Internet address(es):
Main address: www.sciensano.be
Address of the buyer profile: https://enot.publicprocurement.be/enot-war/preViewNotice.do?noticeId=452212
I.1)Name and addresses
Official name: ALLEANZA CONTRO IL CANCRO (ACC)
National registration number: IT09127781004
Postal address: VIA GIORGIO RIBOTTA 5
Town: Roma
NUTS code: IT Italia
Postal code: 00144
Country: Italy
E-mail: roberta.carbone@ieo.it
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.alleanzacontroilcancro.it
I.1)Name and addresses
Official name: INSTITUT CURIE (IC)
National registration number: FR32784257164
Postal address: Rue d'Ulm 26
Town: Paris
NUTS code: FR France
Postal code: 75231
Country: France
E-mail: maud.kamal@curie.fr
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://institut-curie.org/
I.1)Name and addresses
Official name: INSTITUT CATALA D'ONCOLOGIA (ICO)
National registration number: ESQ5856383D
Postal address: AV GRAN VIA DE L'HOSPITALET 199-203
Town: L'HOSPITALET DEL LLOBREGAT
NUTS code: ES España
Postal code: 08908
Country: Spain
E-mail: jmborras@iconcologia.net
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://ico.gencat.cat/en/inici/
I.1)Name and addresses
Official name: INSTITUT JULES BORDET (IJB)
National registration number: BE0257981101
Postal address: RUE HEGER BORDET 1
Town: Brussels
NUTS code: BE100 Arr. de Bruxelles-Capitale / Arr. Brussel-Hoofdstad
Postal code: 1000
Country: Belgium
E-mail: philippe.aftimos@bordet.be
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.bordet.be
I.1)Name and addresses
Official name: LUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN (LMU MUENCHEN)
National registration number: DE811205325
Postal address: GESCHWISTER SCHOLL PLATZ 1
Town: Muenchen
NUTS code: DE Deutschland
Postal code: 80539
Country: Germany
E-mail: martin.dreyling@med.uni-muenchen.de
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.klinikum.uni-muenchen.de
I.1)Name and addresses
Official name: CHARITE - UNIVERSITAETSMEDIZIN BERLIN (HC)
National registration number: DE228847810
Postal address: Chariteplatz 1
Town: Berlin
NUTS code: DE Deutschland
Postal code: 10117
Country: Germany
E-mail: lars.bullinger@charite.de
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.charite.de/en/
I.1)Name and addresses
Official name: HOSPICES CIVILS DE LYON (HCL)
Postal address: QUAI DES CELESTINS 3
Town: Lyon
NUTS code: FR France
Postal code: 69002
Country: France
E-mail: pierre.sujobert@chu-lyon.fr
Internet address(es):
Main address: https://oncngs.eu/
Address of the buyer profile: https://www.chu-lyon.fr/fr
I.2)Information about joint procurement
The contract involves joint procurement
In the case of joint procurement involving different countries, state applicable national procurement law:

This pre-commercial purchase

(PCP) is carried out by SCIENSANO, which has been designated as lead buyer. The applicable national law on contracts

applicable is Belgian law.

I.3)Communication
The procurement documents are available for unrestricted and full direct access, free of charge, at: https://enot.publicprocurement.be/enot-war/preViewNotice.do?noticeId=452212
Additional information can be obtained from the abovementioned address
Tenders or requests to participate must be submitted electronically via: https://eten.publicprocurement.be/etendering/viewWorkspacesBasedOnExtUrl.do?wsName=Sciensano-000-ONCNGS-F02
I.4)Type of the contracting authority
Body governed by public law
I.5)Main activity
Health

Section II: Object

II.1)Scope of the procurement
II.1.1)Title:

Pre-commercial purchases for the acquisition of R & D services for the development of a solution for liquid solid tumour biopsies based on solid NGS. tumours technology, based on NGS technology

Reference number: Sciensano-000-ONCNGS-F02_0
II.1.2)Main CPV code
73100000 Research and experimental development services
II.1.3)Type of contract
Services
II.1.4)Short description:

Compiling the musational profile of tumours requires complex, invasive and costly procedures, but it is

but quickly becomes essential for effective and adequate management of cancer patients, especially when the disease has already reached a metastatic stage.

disease has already reached metastatic stage, where identification of tumour biomarkers is relevant to identify the best

the most targeted therapy. However, access to tumour tissues remains a limiting factor for the assessment of biomarkers, and

more and more evidence suggests that they may even be inadequate to capture clonal heterogeneity that often leads to resistance.

The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative offering the additional opportunity to monitor the evolution of the disease in series.

ability to track the course of the disease in series and obtain a more complete picture of the genetic heterogeneity of the tumour.

genetic heterogeneity of the tumour. However, the current trajectory for the development of large-scale cfDNA tests is highly dependent on expensive, high-throughput centralised sequencing.

expensive, high-speed and centralised, and seems poorly adapted to common practice in Europe.

PCP oncNGS aims to develop an integrated solution for predictive, prognostic and diagnostic analysis of liquid biopsies.

solid tumours (including appropriate haematological indications) based on NGS technology.

This PCP responds to the unmet global need for oncology, which consists of profiling multiple tumours at molecular level in the broadest possible way.

to the widest possible extent, promoting an economically sustainable and decentralised model that allows secure and transparent access to sensitive data.

sensitive data. All partners in this consortium agree that they face a common challenge: provide "the best NGS tests, for

all solid and lymphoid tumours, always”. They agree that a jointly identified public contract meets a need shared by all

the buyers of the group of buyers of the project which is the subject of this proposal for a public procurement contract ‘oncNGS’.

More information on the objective of the PCP oncNGS and the PCP Challenge can be found in the various annexes.

II.1.5)Estimated total value
Value excluding VAT: 7 073 554.00 EUR
II.1.6)Information about lots
This contract is divided into lots: no
II.2)Description
II.2.2)Additional CPV code(s)
33000000 Medical equipments, pharmaceuticals and personal care products
38000000 Laboratory, optical and precision equipments (excl. glasses)
48180000 Medical software package
73100000 Research and experimental development services
73300000 Design and execution of research and development
73000000 Research and development services and related consultancy services
72212460 Analytical, scientific, mathematical or forecasting software development services
72212461 Analytical or scientific software development services
72000000 IT services: consulting, software development, Internet and support
71900000 Laboratory services
II.2.3)Place of performance
NUTS code: BE Belgique / België
Main site or place of performance:

R &Dwill be carried out mainly in Europe.

The tests should take place in Brussels (Be), Paris, Lyon (Fr), Berlin, Munich (GER), Barcelona (Sp), Milan, Rome (It).

II.2.4)Description of the procurement:

Routine profiling of tumours requires complex, invasive and costly procedures, but quickly becomes essential for

effective and adequate treatment of cancer patients, especially when the disease has already reached the metastatic stage.

where the identification of tumour biomarkers is relevant to identify the best targeted therapy. However, access

However, access to tumour tissues remains a limiting factor for the assessment of biomarkers, and growing evidence suggests that it can even be

insufficient to capture the clonal heterogeneity that is often the cause of resistance. The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive tool.

The assessment of circulating biomarkers is rapidly gaining ground as a non-invasive alternative offering an additional opportunity to track the evolution of the disease in series.

the possibility of obtaining a more complete picture of the genetic heterogeneity of the tumour. However, the current development path

However, the current development trajectory for large-scale cfDNA tests is highly dependent on cost-intensive centralised high speed sequencing and seems ill-suited to common practice in Europe.

common practice in Europe.

PCP oncNGS aims to develop an integrated solution for predictive, prognostic and diagnostic analysis of liquid biopsies.

solid tumours (including appropriate haematological indications) based on NGS technology.

This PCP responds to the unmet global need for oncology, which consists of profiling multiple tumours at molecular level in the broadest possible way.

to the widest possible extent, promoting an economically sustainable and decentralised model that allows secure and transparent access to sensitive data.

sensitive data. All partners in this consortium agree that they face a common challenge: provide "the best NGS tests, for

all solid and lymphoid tumours, always”. They agree that a jointly identified public contract meets a need shared by all

the buyers of the group of buyers of the project which is the subject of this proposal for a public procurement contract ‘oncNGS’.

II.2.5)Award criteria
Price is not the only award criterion and all criteria are stated only in the procurement documents
II.2.6)Estimated value
II.2.7)Duration of the contract, framework agreement or dynamic purchasing system
Duration in months: 31
This contract is subject to renewal: no
II.2.10)Information about variants
Variants will be accepted: no
II.2.11)Information about options
Options: no
II.2.13)Information about European Union funds
The procurement is related to a project and/or programme financed by European Union funds: yes
Identification of the project:

This project was funded by the EU’s Horizon 2020 research and innovation programme.

under Grant Agreement No 874467

II.2.14)Additional information

See the attached document Invitation to Tender and the other tender documents.

Section III: Legal, economic, financial and technical information

III.1)Conditions for participation
III.1.3)Technical and professional ability
Minimum level(s) of standards possibly required:

Class: N/A, Category: N/A

Section IV: Procedure

IV.1)Description
IV.1.1)Type of procedure
Open procedure
IV.1.3)Information about a framework agreement or a dynamic purchasing system
The procurement involves the establishment of a framework agreement
Framework agreement with several operators
IV.1.8)Information about the Government Procurement Agreement (GPA)
The procurement is covered by the Government Procurement Agreement: no
IV.2)Administrative information
IV.2.1)Previous publication concerning this procedure
Notice number in the OJ S: 2021/S 076-194474
IV.2.2)Time limit for receipt of tenders or requests to participate
Date: 17/10/2022
Local time: 14:00
IV.2.3)Estimated date of dispatch of invitations to tender or to participate to selected candidates
IV.2.4)Languages in which tenders or requests to participate may be submitted:
English, French, Dutch
IV.2.7)Conditions for opening of tenders
Date: 17/10/2022
Local time: 14:00

Section VI: Complementary information

VI.1)Information about recurrence
This is a recurrent procurement: no
VI.3)Additional information:
VI.4)Procedures for review
VI.4.1)Review body
Official name: Conseil d'Etat
Town: Bruxelles
Postal code: 1040
Country: Belgium
VI.5)Date of dispatch of this notice:
11/07/2022